Cellular Origin News Today

Cellular Origins and the Cell and Gene Therapy Catapult (CGT Catapult) have announced a new collaboration to demonstrate universal automation of CGT manufacturing.

Partnership to develop and implement Cellular Origins' robotic platform Constellation for universal automation of CGT manufacturing at CGT Catapult's Stevenage Manufacturing Innovation Centre Cellular

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and the Cell and Gene Therapy Catapult (CGT Catapult), an independent innovation and technology organisation specializing in the advancement of the cell and gene therapy industry, today announced a collaboration to demonstrate universal automation of CGT manufacturing.

TTP Company Cellular Origins has appointed Peter Crossley as Chief Operating Officer (COO), to bolster Cellular Origins’ mission to develop scalable automation solutions for cell therapy manufacture. Click to read more...

Renowned experts from across the CGT and robotics industries, Professor John Campbell, Dr Matthew Li, Dr Paul Roberts, and Geoffrey Hodge appointed to provide strategic and technical perspectives.

Closed, fully automated, and configurable robotic platform for cell therapy manufacture can achieve 30-fold increase in space efficiency and reduces production costs and labour by 51% and 16-fold

A closed, fully automated, and configurable robotic platform for cell therapy manufacture can achieve 30-fold increase in space efficiency and reduces production costs and labor by 51% and 16-fold, respectively.

Partnership aims to integrate ScaleReady's CGT manufacturing workflow with Cellular Origins' robotic technology Initially focussed on automation of ScaleReady's G-Rex platform Cellular Origins

Cellular Origins a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs).

Cellular Origins has partnered with ScaleReady, to automate portions of its cell and gene therapies (CGT) manufacturing workflow using a robotics system for sterile liquid transfer.